
CLINICAL TRIAL PROTOCOL SUMMARY Protocol Number: CT-2024-001 Study Title: Phase III Efficacy Study of Investigational Drug XYZ

STUDY OBJECTIVES: Primary Objective: To evaluate the efficacy of Drug XYZ in reducing symptom severity compared to placebo. Secondary Objectives: To assess safety, tolerability, and quality of life improvements.

STUDY DESIGN: This is a randomized, double-blind, placebo-controlled, multicenter study. Duration: 24 weeks of treatment followed by 4 weeks of follow-up. Sample Size: 300 participants (150 per arm).

INCLUSION CRITERIA:

- Age 18-65 years
- Confirmed diagnosis of the target condition
- Symptom severity score â‰¥ 15 at screening
- Willing and able to provide informed consent
- Adequate organ function (liver, kidney, cardiac)

EXCLUSION CRITERIA:

- Pregnant or breastfeeding
- History of severe allergic reactions
- Current use of prohibited medications
- Participation in another clinical trial within 30 days
- Known hypersensitivity to study drug components

DOSING: Drug XYZ: 100mg orally twice daily Placebo: Matching placebo twice daily

ASSESSMENTS:

- Screening visit (Day -14 to Day -1)
- Baseline visit (Day 1)
- Follow-up visits at Weeks 4, 8, 12, 16, 20, 24
- Final follow-up at Week 28

PRIMARY ENDPOINT: Change from baseline in symptom severity score at Week 24.

SAFETY MONITORING: Adverse events will be collected at each visit and graded according to CTCAE v5.0. Serious adverse events must be reported within 24 hours.
